HHV-6B reactivation affects approximately half of all allogeneic hematopoietic cell transplant
(HCT) recipients. HHV-6B is the most frequent infectious cause of encephalitis following …

Abstract Human herpesvirus 6 (HHV6) viremia is a common cause of morbidity following
allogeneic hematopoietic cell transplantation (HCT). We previously associated T-cell …

Abstract Human herpesvirus 6 (HHV-6) can reactivate after allogeneic hematopoietic stem
cell transplant (allo-HSCT) and may lead to severe symptoms. HHV-6–specific immune …

Early human herpesvirus 6 (HHV6) reactivation after hematopoietic stem cell transplantation
(HSCT) is associated with poor survival. We characterized HHV6 immuneresponses in …

Human herpesvirus 6 (HHV-6) reactivation has been associated with acute graft-versus-host-
disease (aGVHD), cytomegalovirus reactivation, and mortality after allogeneic hematopoietic …

This study investigated the impact of human herpesvirus type 6 (HHV6) reactivation within
100 days of allogeneic stem cell transplantation (allo-SCT) on patient outcomes. HHV6 …

Although human herpesvirus 6 (HHV-6) has been considered an important opportunistic
and potentially fatal pathogen for allogeneic hematopoietic stem cell transplantation (HSCT) …

Background. Although human herpesvirus 6 (HHV-6) is known to reactivate during
hematopoietic stem cell transplantation (HSCT), the clinical significance of this finding is …

Reactivation of human herpesvirus 6 (HHV-6) after allogeneic hematopoietic cell
transplantation (HCT) is associated with neurologic complications, but the impact of donor …

Human herpesvirus type 6 (HHV6) is known to reactivate after hematopoetic stem cell
transplantation (HSCT) and has been suggested to be associated with increased mortality …